Healthcare Providers and Services
Company Overview of Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center, a cancer hospital, provides cancer treatment services. It offers adult and pediatric cancer care services; specialized treatments and services, including adult blood and marrow stem cell transplantation, pediatric blood and marrow transplantation, and pathology consulting; and symptom management services, such as integrative medicine, palliative care and pain management, rehabilitation, dermatologic health, and cognitive testing. The company also provides services in the areas of counseling, dermatology, fertility, genetic testing and counseling, integrative medicine, nutrition, rehabilitation, resources for life after cancer program, sexual health, an...
1275 York Avenue
New York, NY 10065
Founded in 1884
Key Executives for Memorial Sloan-Kettering Cancer Center
Chief Executive Officer and President
Senior Vice President of Finance
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2014.
Memorial Sloan-Kettering Cancer Center Key Developments
Atara Biotherapeutics Enters into Immunotherapy Alliance with Memorial Sloan Kettering Cancer Center to Develop and Commercialize Allogeneic T-cell Therapies
Sep 24 14
Atara Biotherapeutics has entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center to develop and commercialize allogeneic T-cell therapies to treat certain cancers and persistent viral infections. As part of the deal, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies. These therapies include T-cells activated against Epstein Barr Virus, or EBV (Phase 2); T-cells activated against cytomegalovirus, or CMV (Phase 2); and T-cells activated against Wilms Tumor 1, or WT1 (Phase 1). These three programs share a common technology under which third-party donor-derived whole blood is collected and enriched for T lymphocytes (T-cells), which are then exposed to certain antigens, and the resulting activated T-cells are characterized and stored for future therapeutic use. Under the deal, MSK will receive cash and Atara common stock in return for the exclusive option. In case Atara exercises its option to enter into the license deal, MSK will receive an upfront license payment and will be eligible to secure additional payments based on achievement of certain development, regulatory and sales-related milestones as well as royalty payments. Both the firms have agreed to collaborate on further research to develop additional cellular therapies, which may include T-cell therapies against other antigens and/or chimeric antigen receptor-modified T-cells, known as CAR-T.
Memorial Sloan-Kettering Cancer Center Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 01:30 PM
Sep 10 14
Memorial Sloan-Kettering Cancer Center Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 01:30 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Isabelle Rivière, Director, Cell Therapy and Cell Engineering Facility.
MabVax Therapeutics Holdings, Inc. Enters into Agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics
Sep 10 14
MabVax Therapeutics Holdings Inc. announced it has entered into agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the company's internally developed antibody discovery platform. Under the agreements, MabVax will supply unique targeting sequences from the fully-human antibodies to MSK. Pursuant to the agreement with MSK, researchers at MSK will conduct the early stage research and development of Chimeric Antigen Receptor (CAR) T-cell therapeutics using the MabVax antibody sequences and then test them both in vitro and in animal models with the objective of producing anti-cancer therapeutics targeting certain solid tumors. MabVax and Juno entered into an exclusive option agreement giving Juno the right to negotiate a license agreement for exclusive rights to any CAR T-cell therapeutic products using the antibody sequences provided to MSKCC.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|